Research programme: cardiovascular disorders therapy - Merck/FoxHollow Technologies

Drug Profile

Research programme: cardiovascular disorders therapy - Merck/FoxHollow Technologies

Alternative Names: Atherosclerosis therapy research programme - Merck & Co/FoxHollow Technologies

Latest Information Update: 19 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator FoxHollow Technologies; Merck & Co
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis; Cardiovascular disorders

Most Recent Events

  • 05 Mar 2008 This programme is still in active development
  • 27 Sep 2006 Merck & Co. expands the scope of its worldwide strategic research collaboration with FoxHollow Technologies
  • 14 Sep 2005 Preclinical trials in Atherosclerosis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top